Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Derivative Liability of $11MM?
View:
Post by Bookworm28 on Jun 09, 2021 2:20pm

Derivative Liability of $11MM?

Just looking at the March 31, 2021 financials. What is the $11MM liability in their balance sheet, for derivatives? Then, is looks like a $7MM loss, and further down, it's a plus in their cash flow? 

It looks like a $7MM accounting exercise more than an actual loss or gain? Is this correct?

Thanks for helping out. It doesn't appear to be material. Just seeing if y'all agree.
Comment by M101 on Jun 09, 2021 2:59pm
Google debenture financing for the book keeping requirements, you'll see how it creates a derivative and why it requires less than obvious entries across the balance sheet and income statement.  Where has Actuarial been recently?